BACKGROUND AND OBJECTIVES: Anemia is an early complication of CKD that is associated with increased morbidity and mortality. Prior data show associations between abnormal mineral metabolism markers and decreased erythropoiesis. However, few studies have investigated elevated fibroblast growth factor 23 as a risk factor for the development of anemia in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a prospective cohort study of 3869 individuals with mild to severe CKD enrolled in the Chronic Renal Insufficiency Cohort Study between 2003 and 2008 and followed through 2013. We hypothesized that elevated baseline fibroblast growth factor 23 levels are associated with prevalent anemia, decline in hemoglobin over time, and development of incident anemia, defined as serum hemoglobin level <13 g/dl in men, serum hemoglobin level <12 g/dl in women, or use of erythropoietin stimulating agents. RESULTS: In the 1872 of 3869 individuals who had prevalent anemia at baseline, mean age was 58 (11) years old, and mean eGFR was 39 (13) ml/min per 1.73 m2. Higher levels of fibroblast growth factor 23 were significantly associated with prevalent anemia (odds ratio per 1-SD increase in natural log-transformed fibroblast growth factor 23, 1.39; 95% confidence interval, 1.26 to 1.52), decline in hemoglobin over 4 years, and risk of incident anemia (hazard ratio per 1-SD increase in natural log-transformed fibroblast growth factor 23, 1.13; 95% confidence interval, 1.04 to 1.24; quartile 4 versus quartile 1: hazard ratio, 1.59; 95% confidence interval, 1.19 to 2.11) independent of demographic characteristics, cardiovascular disease risk factors, CKD-specific factors, and other mineral metabolism markers. The results of our prospective analyses remained unchanged after additional adjustment for time-varying eGFR. CONCLUSIONS: Elevated fibroblast growth factor 23 is associated with prevalent anemia, change in hemoglobin over time, and development of anemia. Future studies are needed to elucidate the mechanisms for these associations.
BACKGROUND AND OBJECTIVES:Anemia is an early complication of CKD that is associated with increased morbidity and mortality. Prior data show associations between abnormal mineral metabolism markers and decreased erythropoiesis. However, few studies have investigated elevated fibroblast growth factor 23 as a risk factor for the development of anemia in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a prospective cohort study of 3869 individuals with mild to severe CKD enrolled in the Chronic Renal Insufficiency Cohort Study between 2003 and 2008 and followed through 2013. We hypothesized that elevated baseline fibroblast growth factor 23 levels are associated with prevalent anemia, decline in hemoglobin over time, and development of incident anemia, defined as serum hemoglobin level <13 g/dl in men, serum hemoglobin level <12 g/dl in women, or use of erythropoietin stimulating agents. RESULTS: In the 1872 of 3869 individuals who had prevalent anemia at baseline, mean age was 58 (11) years old, and mean eGFR was 39 (13) ml/min per 1.73 m2. Higher levels of fibroblast growth factor 23 were significantly associated with prevalent anemia (odds ratio per 1-SD increase in natural log-transformed fibroblast growth factor 23, 1.39; 95% confidence interval, 1.26 to 1.52), decline in hemoglobin over 4 years, and risk of incident anemia (hazard ratio per 1-SD increase in natural log-transformed fibroblast growth factor 23, 1.13; 95% confidence interval, 1.04 to 1.24; quartile 4 versus quartile 1: hazard ratio, 1.59; 95% confidence interval, 1.19 to 2.11) independent of demographic characteristics, cardiovascular disease risk factors, CKD-specific factors, and other mineral metabolism markers. The results of our prospective analyses remained unchanged after additional adjustment for time-varying eGFR. CONCLUSIONS: Elevated fibroblast growth factor 23 is associated with prevalent anemia, change in hemoglobin over time, and development of anemia. Future studies are needed to elucidate the mechanisms for these associations.
Authors: A Levin; C R Thompson; J Ethier; E J Carlisle; S Tobe; D Mendelssohn; E Burgess; K Jindal; B Barrett; J Singer; O Djurdjev Journal: Am J Kidney Dis Date: 1999-07 Impact factor: 8.860
Authors: James P Lash; Alan S Go; Lawrence J Appel; Jiang He; Akinlolu Ojo; Mahboob Rahman; Raymond R Townsend; Dawei Xie; Denise Cifelli; Janet Cohan; Jeffrey C Fink; Michael J Fischer; Crystal Gadegbeku; L Lee Hamm; John W Kusek; J Richard Landis; Andrew Narva; Nancy Robinson; Valerie Teal; Harold I Feldman Journal: Clin J Am Soc Nephrol Date: 2009-06-18 Impact factor: 8.237
Authors: Fenna van Breda; Mireille E Emans; Karien van der Putten; Branko Braam; Frans J van Ittersum; Rob J Kraaijenhagen; Martin H de Borst; Marc Vervloet; Carlo A J M Gaillard Journal: PLoS One Date: 2015-06-16 Impact factor: 3.240
Authors: Tamara Isakova; Xuan Cai; Jungwha Lee; Dawei Xie; Xue Wang; Rupal Mehta; Norrina B Allen; Julia J Scialla; Michael J Pencina; Amanda H Anderson; John Talierco; Jing Chen; Michael J Fischer; Susan P Steigerwalt; Mary B Leonard; Chi-Yuan Hsu; Ian H de Boer; John W Kusek; Harold I Feldman; Myles Wolf Journal: J Am Soc Nephrol Date: 2017-11-22 Impact factor: 10.121
Authors: Mark R Hanudel; Michele F Eisenga; Maxime Rappaport; Kristine Chua; Bo Qiao; Grace Jung; Victoria Gabayan; Barbara Gales; Georgina Ramos; Maarten A de Jong; Jelmer J van Zanden; Martin H de Borst; Stephan J L Bakker; Elizabeta Nemeth; Isidro B Salusky; Carlo A J M Gaillard; Tomas Ganz Journal: Nephrol Dial Transplant Date: 2019-12-01 Impact factor: 5.992
Authors: Arezoo Daryadel; Carla Bettoni; Thomas Haider; Pedro H Imenez Silva; Udo Schnitzbauer; Eva Maria Pastor-Arroyo; Roland H Wenger; Max Gassmann; Carsten A Wagner Journal: Pflugers Arch Date: 2018-07-02 Impact factor: 3.657